Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glioblastoma Start-Ups Get Specific

This article was originally published in Start Up

Executive Summary

For start-ups developing novel and risky medicines to treat glioblastoma, a rare, invasive form of brain cancer, the Pfizer/Avant deal was a watershed moment: It signaled the vigorous interest of a pharmaceutical behemoth in a disease where patients number in just the tens of thousands. The positive effects are likely to be felt in executive suites of biotechs developing therapeutics for this grievous disease.
Advertisement

Related Content

Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch
Slower Deal-Making Year In Oncology Leaves Numerous Appealing Targets
Biotechs Show Off Early-Stage Progress At AACR Meeting
Start-Up Previews (07/2008)
MedGenesis Therapeutix Inc.
Hy BioPharma Inc.
Pharmaxon SA
SanoGene Therapeutics Inc.
Genmab To Initiate HuMax-Inflam Glioblastoma Trial In 2008

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel